The Cardiovascular Disease Pipeline: A Strategic Review
Decision Resources
April 27, 2009 30 Pages - SKU: DECR2272744
|
|
Introduction
The robust and diverse cardiovascular disease (CVD) R&D pipeline is evidence of companies'awareness that these diseases remain leading causes of death worldwide, and that the chronic nature of many CVDs offers significant commercial opportunity. Drug developers have populated their pipelines with novel approaches and new mechanisms of action that seek to fulfill unmet needs and tap remaining therapeutic opportunities. This pipeline activity, combined with the generic entry of current market-leading agents, will help to establish new leaders in the cardiovascular market.
Get the Answers You Need to Shape Your Strategy
- The CVD market has experienced strong growth thanks to the emergence of efficacious drug classes to treat chronic conditions. What is the size of the CVD market? What are the leading drug classes and agents? Which companies hold the greatest market share?
- The high CVD mortality rate signals the need for more-efficacious treatments. Which companies are developing new CVD treatments? Which diseases are primary focuses of development?
Will emerging agents establish a new market leader?
- An abundance of generic CVD agents challenges the uptake of novel treatments. What opportunities remain in the CVD market? How can drug developers maximize their chances of success?
Scope
- 2008 market: 2008 sales; leading drug classes; market-leading companies; commercial position of leading agents.
- The cardiovascular disease pipeline: Number of agents in development; disease focus; active companies; profiles of Merck and Solvay.
- Opportunities in cardiovascular disease: Fixed-dose combinations; growth of the anticoagulant market.
- Outlook: Impact of generic erosion; outlook to 2014; impact of the Merck/Schering-Plough merger.
Diseases Mentioned in This Spectrum Report
- Acute coronary syndrome
- Acute heart failure
- Atrial fibrillation
- Chronic heart failure
- Coronary heart disease
- Dyslipidemia
- Hypertension
- Post-myocardial infarction
- Venous thromboembolism
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Cardiovascular Disease Pipeline
- Emerging Agents Target Unmet Needs
- Notable Players in the Cardiovascular Disease Sector
- Companies Leading the Cardiovascular Disease Market Have Much to Lose
- Merck
- Solvay
- Key Areas of Opportunity in the Cardiovascular Disease Pipeline
- Combination Drugs
- The Anticoagulant Market
- Outlook: Can Emerging Agents Mitigate Generic Erosion?
- Current Market Statistics
- Challenges and Opportunities for Emerging Agents
- Tables
- 1. Cardiovascular Diseases: Definitions and Common Drug Class Treatments
- 2. Drug Classes Commonly Prescribed to Treat Cardiovascular Disease
- 3. Market-Leading Companies, 2008
- 4. Merck’s Cardiovascular Pipeline
- 5. Solvay’s Cardiovascular Pipeline
- 6. Fixed-Dose Combination Agents in Clinical Development
- 7. Anticoagulants in Clinical Development
- 8. Top-Selling Cardiovascular Drugs, 2008
- 9. Key Patent Expiries for Market-Leading Companies
- Figures
- 1. Cardiovascular Pipeline by Development Phase
- 2. Cardiovascular Pipeline by Disease
- 3. Late-Stage Development Agents, Chronic Versus Acute Therapies
- 4. Development Activity, by Company Size
- 5. Leading Cardiovascular Pipelines, by Number of Agents
- 6. Leading Cardiovascular Pipelines: Number of Agents by Disease
- 7. Pfizer Cardiovascular Franchise Sales, 2008
- 8. Sanofi-Aventis Cardiovascular Franchise Sales, 2008
- 9. Merck Cardiovascular Sales, 2003-2008
- 10. Cardiovascular Disease Market Growth, 2003-2008
- 11. Worldwide Sales of Cardiovascular Drug Classes, 2008
- 12. Cardiovascular Disease Market Growth by Region, 2003-2008
Share this report
Other tasks Related Markets Cardiovascular Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
